Bismuth(III) 5-sulfosalicylate complexes: structure, solubility and activity against Helicobacter pylori

Study of the preparation, characterization, and solubility of lidocaine complexed with 5-sulfosalicylic acid dihydrate

OBJECTIVE

This study was to prepare solid dispersions of lidocaine (Lid) with 5-sulfosalicylic acid dihydrate (SSA) by freeze-drying (freeze-dried [FD] Lid/SSA = 1/1) and to evaluate their physical properties.

METHODS

Here, we evaluated the physicochemical properties and solubility of solid dispersions of Lid and SSA prepared by freeze-drying (freeze-dried [FD] Lid/SSA = 1/1).

RESULTS

Differential scanning calorimetry measurements showed that after freeze-drying, the endothermic peak due to Lid melting, the dehydration peak, and the endothermic peak due to SSA melting disappeared. Powder X-ray diffraction results showed that the characteristic Lid and SSA peaks disappeared after freeze-drying, indicating a halo pattern. The near-infrared spectroscopy results suggested that Lid-derived -NH and -CH groups and the Lid-derived -OH and -CH groups from the SSA peak shifted and broadened after freeze-drying, suggesting their involvement in complex formation through Lid/SSA intermolecular interactions. Nuclear Overhauser effect spectroscopy-nuclear magnetic resonance (NMR) measurements showed a cross-peak due to the interaction between the Lid-derived -CH group and the SSA-derived -OH group, suggesting hydrogen bonding. Diffusion-ordered spectroscopy NMR measurements showed that the diffusion coefficients of Lid and SSA aggregated in FD Lid/SSA, suggesting a change in Lid dispersibility in the solvent owing to the formation of a complex with SSA. The solubility of FD Lid/SSA was approximately 88 mg/mL (∼20-fold higher than that of Lid).

CONCLUSIONS

These findings suggest that complex formation occurred in FD Lid/SSA; this enhanced the solubility of this dispersion.

Bioactive Bismuth Compounds: Is Their Toxicity a Barrier to Therapeutic Use?

Bismuth compounds are considered relatively non-toxic, with their low solubility in aqueous solutions (e.g., biological fluids) being the major contributing factor to this property. Bismuth derivatives are widely used for the treatment of peptic ulcers, functional dyspepsia, and chronic gastritis. Moreover, the properties of bismuth compounds have also been extensively explored in two main fields of action: antimicrobial and anticancer. Despite the clinical interest of bismuth-based drugs, several side effects have also been reported. In fact, excessive acute ingestion of bismuth, or abuse for an extended period of time, can lead to toxicity. However, evidence has demonstrated that the discontinuation of these compounds usually reverses their toxic effects. Notwithstanding, the continuously growing use of bismuth products suggests that it is indeed part of our environment and our daily lives, which urges a more in-depth review and investigation into its possible undesired activities. Therefore, this review aims to update the pharmaco-toxicological properties of bismuth compounds. A special focus will be given to in vitro, in vivo, and clinical studies exploring their toxicity.

Structural Insights into New Bi(III) Coordination Polymers with Pyridine-2,3-Dicarboxylic Acid: Photoluminescence Properties and Anti-Helicobacter pylori Activity

Two novel coordination polymers, [Bi2(2,3pydc)2(2,3pydcH)2(H2O)]n (1) and {(Et3NH)2[Bi(2,3pydc)(2,3pydcH)Cl2]}n (2) were prepared using as a prolinker pyridine-2,3-dicarboxylic acid (2,3pydcH2). The obtained complexes were fully characterized by elemental analysis, TG/DTG, FT-IR, solid-state photoluminescence, DFT calculations and single-crystal X-ray diffraction. The obtained complexes crystallized in the triclinic P-1 space group (1) and comprise dimeric units with two crystallographically different Bi(III) centers (polyhedra: distorted pentagonal bipyramid and bicapped trigonal prism) and monoclinic P21/c space group (2) with a distorted monocapped pentagonal bipyramid of Bi(III) center. The various coordination modes of bridging carboxylate ligands are responsible for the formation of 1D chains with 4,5C10 (1) and 2C1 (2) topology. The photoluminescence quantum yield for polymer 2 is 8.36%, which makes it a good candidate for more specific studies towards Bi-based fluorescent materials. Moreover, it was detected that polymer 1 is more than twice as active against H. pylori as polymer 2. It can be concluded that there is an existing relationship between the structure and the antibacterial activity because the presence of chloride and triethylammonium ions in the structure of complex 2 reduces the antibacterial activity.

Syntheses and Molecular Structures of Heteroleptic and Homoleptic Antimony(III) Tetrafluorophenylethylenediamidate Complexes

A series of hetero- and homoleptic organoamidoantimony(iii) complexes of the type [SbLMe3−nCln] (n=2, 1, 0) (HLMe=p-HC6F4NH(CH2)2NMe2) incorporating a bulky amido fluorinated ligand tethered with an amino pendant arm, have been successfully synthesised and fully characterised as monomers in the solid state. [Sb(p-HC6F4NC2H4NMe2)Cl2] (1), [Sb(p-HC6F4NC2H4NMe2)2Cl] (2), and [Sb(p-HC6F4NC2H4NMe2)3] (3) were isolated by metathesis reactions involving different stoichiometric ratios between SbCl3 and Li(p-HC6F4N(CH2)2NMe2) (LiLMe) in non-coordinating solvents, while [Sb(p-HC6F4NC2H4NMe2)Cl2] (1) was also synthesised by the direct reaction between SbCl3 and HLMe in THF providing an interesting alternative pathway to access these types of compounds.

Impact of substituents on the crystal structures and anti-leishmanial activity of new homoleptic Bi(iii) dithiocarbamates

Anti-leishmanial activity of six structurally characterised new functionalised homoleptic Bi(iii) dithiocarbamate complexes having monomeric, dimeric and rare polymeric structures has been explored.

Multiparameter High-Throughput and in Situ X-ray Diffraction Study of Six New Bismuth Sulfonatocarboxylates: Discovery, Phase Transformation, and Reaction Trends

With the employment of high-throughput methods, the system Bi³⁺/4,8-disulfonyl-2,6-naphthalenedicarboxylic acid (H₄DSNDC)/H₂O/additive (HNO₃ or NaOH) was systematically investigated under hydrothermal reaction conditions. The influence of the molar ratio of the starting materials, pH, and reaction temperature and time was investigated in more than 500 reactions. The product formation is highly sensitive toward small changes of the synthesis parameters, but six new bismuth sulfonatocarboxylates were reproducibly obtained starting from clear solutions of the reactants. All compounds were structurally characterized from single-crystal X-ray diffraction data. Fully deprotonated linker ions are found in [Bi₆O₆(OH)₂(H₂O)₄(DSNDC)] (1), [Bi₂(OH)₂(DSNDC)] (2), [Bi₈O₇(OH)₂(H₂O)₂(DSNDC)₂] (3), and [Bi₇O₅(OH)₃(H₂O)₄(DSNDC)₂]·4H₂O (4), while the presence of larger amounts of acid or short reaction times leads to compounds with noncoordinating -COOH groups, [Bi₂(OH)₂(H₂O)₂(DSNDC)(H₂DSNDC)] (5) and [Bi₆O₄(OH)₄(H₂O)₁₂(H₂DSNDC)₃]· xH₂O (6), respectively. The inorganic building units (IBUs) in all six structures differ substantially from each other; the IBUs found in 2 ({Bi₂(OH)₂}), 5 (BiO₈ polyhedron), and 6 ({Bi₆O₄(OH)₄} cluster) have been reported in the literature, while new IBUs are observed for 1 (chains of composition {Bi₃O₃(OH)}_∞), 3 ({Bi₁₆O₁₄(OH)₄} cluster), and 4 ({Bi₇O₅(OH)₃} cluster). Systematic variation of the reaction temperature and time indicated their distinct influence on product formation. Hence, in situ powder X-ray diffraction measurements at Deutsches Elektronen-Synchrotron, Hamburg, Germany, employing synchrotron radiation were carried out. In all studied in situ reactions, compound 6 is first observed and subsequently transformed to 1, 2, 4, and 5, depending on the reaction time and temperature as well as concentration of the starting materials.

Role of Bismuth in the Eradication of Helicobacter pylori

Bismuth salts exert their activity within the upper gastrointestinal tract through action of luminal bismuth. Bismuth exerts direct bactericidal effect on Helicobacter pylori by different ways: forms complexes in the bacterial wall and periplasmic space, inhibits different enzymes, ATP synthesis, and adherence of the bacteria to the gastric mucosa. Bismuth also helps ulcer healing by acting as a barrier to the aggressive factors and increasing mucosal protective factors such as prostaglandin, epidermal growth factor, and bicarbonate secretion. To date, no resistance to bismuth has been reported. Also synergism between bismuth salts and antibiotics was present. It was shown that metronidazole and clarithromycin resistant H. pylori strains become susceptible if they are administered together with bismuth. Bismuth-containing quadruple therapy was recommended both by the Second Asia-Pacific Consensus Guidelines and by the Maastricht IV/Florence Consensus Report as an alternative first choice regimen to standard triple therapy, in areas with low clarithromycin resistance, and it is recommended as the first-line therapeutic option in areas with a high prevalence of clarithromycin resistance. Greater than 90% eradication success can be obtained by bismuth-containing quadruple therapy. Choosing bismuth as an indispensable part of first-line therapy is logical as both metronidazole and clarithromycin resistances can be overcome by adding bismuth to the regimen.

Structural influences on the activity of bismuth(III) indole-carboxylato complexes towards Helicobacter pylori and Leishmania

Seven new bismuth(III) complexes derived from indole-carboxylic acids have been synthesised: five are homoleptic; [Bi(IAA)₃] B1, [Bi(IPA)₃] B2, [Bi(IBA)₃] B3, [Bi(MICA)₃] B4, [Bi(IGA)₃] B6, and two are heteroleptic [BiPh(MICA)₂] B5 (where IAA-H=2-(1H-indol-3-yl)acetic acid, IPA-H=3-(1H-indol-3-yl)propanoic acid, IBA-H=4-(1H-indol-3-yl)butanoic acid, IGA-H=2-(1H-indol-3-yl)-2-oxoacetic acid, and MICA-H=1-methyl-1H-indole-3-carboxylic acid). All complexes were fully characterised by elemental analysis, infrared and mass-spectroscopy, and nuclear magnetic resonance (¹H, ¹³C) spectroscopy. Complex [BiPh(IGA)₂] B7 is structurally authenticated by X-ray crystallography as a dimer in the solid-state. The in-vitro anti-bacterial activity of the indole-carboxylic acids and their bismuth(III) complexes was assessed against Helicobacter pylori. While the acids were non-toxic at <100μgmL^-1, all the bismuth compounds showed an MIC of 6.25μgmL^-1, indicating that the anti-bacterial activity is insensitive to the degree of substitution at the Bi(III) centre or the composition of the indole-carboxylate ligands. All compounds were further tested for their anti-parasitic activity against Leishmania major and for their toxicity towards mammalian cells. From the anti-parasitic studies, it was found that the heteroleptic bismuth(III) complexes are the most active, with B5 and B7 showing comparable activity to Amphotericin B, without any toxicity towards the mammalian cells at their effective concentration.

Synthesis and crystal structure of three new bismuth(III) arylsulfonatocarboxylates

Three new bismuth arylsulfonatocarboxylates [Bi(OH)(SB)] (1), [Bi4(ST)2(HST)O2(H2O)2]·H2O (2) and [Bi4(ST)2O3(H2O)2] (3) were synthesized under solvothermal reaction conditions at 180°C using the potassium or sodium salt of 4-sulfobenzoic acid (H2SB) and 2-sulfoterephthalic acid (H3ST), respectively. The compounds were characterized in detail and the crystal structures were determined from single crystal X-ray diffraction data. Phase purity was confirmed by powder X-ray diffraction and elemental analysis. Structural comparisons to the only three other known bismuth sulfonatocarboxylates are presented. Due to the higher reaction temperatures employed for the synthesis of the title compounds a higher degree of condensation of the BiOx polyhedra (X=7 or 8) to tetrameric units, 1D chains or a 2D layer is observed. Connection through the organic linker molecules leads to the formation of 3D coordination polymers in all three title compounds.

Current and potential applications of bismuth-based drugs

: Bismuth compounds have been used extensively as medicines and in particular for the treatment of gastrointestinal ailments. In addition to bismuth's well known gastroprotective effects and efficacy in treating H. pylori infection it also has broad anti-microbial, anti-leishmanial and anti-cancer properties. Aspects of the biological chemistry of bismuth are discussed and biomolecular targets associated with bismuth treatment are highlighted. This review strives to provide the reader with an up to date account of bismuth-based drugs currently used to treat patients and discuss potential medicinal applications of bismuth drugs with reference to recent developments in the literature. Ultimately this review aims to encourage original contributions to this exciting and important field.

Bismuth(iii) complexes derived from α-amino acids: the impact of hydrolysis and oxido-cluster formation on their activity against Helicobacter pylori

Bi(iii) complexes, [BiL₃] and [Bi₂L₃], derived from α-amino acids (LH) have been synthesised and characterised. Hydrolysis and oxido-cluster formation in water impacts significantly on their activity towardsH. pylori.

Bismuth(III) β-thioxoketonates as antibiotics against Helicobacter pylori and as anti-leishmanial agents

Nine different β-thioxoketones of general formula R(1)C(=O)CH2C(=S)R(2) (R(1) = C6H5, R(2) = C6H5L1; R(1) = C6H5, R(2) = p-CF3C6H4L2; R(1) = p-MeOC6H4, R(2) = C6H5L3; R(1) = p-MeOC6H4, R(2) = p-CF3C6H4L4; R(1) = C5H4N, R(2) = C6H5L5; R(1) = p-IC6H4, R(2) = C6H5L6; R(1) = C6H5, R(2) = p-IC6H4L7; R(1) = C6H5, R(2) = C10H7L8 and R(1) = CH3, R(2) = C6H5L9) and their tris-substituted bismuth(III) complexes having the general formula [Bi{R(1)C(=O)CHC(=S)R(2)}3] were synthesised and fully characterised. The solid state structure of [Bi{C5H4NC(=O)CHC(=S)C6H5}3] B5 was determined by crystallography and revealed that the three β-thioxoketonato ligands are bound to bismuth(III) centre in a bidentate fashion through O and S atoms. The bismuth(III) complexes and the corresponding thioxoketones were assessed for their activity against H. pylori. All of the bismuth(III) complexes were highly active against H. pylori having a MIC of greater than or equal to 3.125 μg mL(-1), while the free acids were essentially not toxic to the bacteria. The anti-leishmanial activity of all the bismuth(III) β-thioxoketonates and the corresponding free acids were assessed against L. major promastigotes. The toxicity towards human fibroblast cells was also assessed. All of the free β-thioxoketones were selectively toxic to the L. major promastigotes displaying some potential as anti-leishmanial agents. Among these [C6H5C(=O)CH2C(=S)C6H5] L1 and [C5H4NC(=O)CH2C(=S)C6H5] L5 showed comparable activity to that of Amphotericin B, killing about 80% of the L. major promastigotes at a concentration of 25 μM (6.0 μg mL(-1)). The bismuth(III) β-thioxoketonate complexes were toxic to both the L. major promastigotes and fibroblast cells at high concentrations, but gave no improvement in anti-leishmanial activity over the free β-thioxoketones.

Bismuth compounds in medicinal chemistry

In recent years, the chemical potential of bismuth and bismuth compounds has been actively exploited. Bismuth salts are known for their low toxicity, making them potential valuable reagents for large-scale synthesis, which becomes more obvious when dealing with products such as active pharmaceutical ingredients or synthetic intermediates. Conversely, bismuth compounds have been widely used in medicine. After extensive use in the treatments of syphilis and other bacterial infections before the advent of modern antibiotics, bismuth compounds remain important for the treatment of several gastrointestinal disorders and also exhibit antimicrobial properties and cytotoxic activity, among others. This review updates relevant advances in the past few years, concerning the application of bismuth reagents and catalysts in innovative synthetic processes for the preparation of compounds of medicinal interest, as well as the preparation, biological evaluation and potential medicinal uses of bismuth compounds.

Remarkable in vitro bactericidal activity of bismuth(III) sulfonates against Helicobacter pylori

Four new tris-substituted bismuth(III) sulfonates of general formula [Bi(O(3)SR)(3)] (R = phenyl 1, p-tolyl 2, 2,4,6-mesityl 3 and S-(+)-10-camphoryl 4) have been synthesised and characterised. Their synthesis by solvent-free (SF) and solvent-mediated (SM) methods has been explored and their activity against Helicobacter pylori has been investigated. The compounds 1-4 display a remarkable in vitro activity against three laboratory strains of H. pylori (B128, 26,695 and 251) with minimum inhibitory concentration (MIC) values as low as 0.049 μg mL(-1) for the strains B128 and 26,695, and 0.781 μg mL(-1) for the clinical isolate 251. This places most MIC values in the nano-molar region and demonstrates the strong influence of the sulfonate group on the bactericidal properties. The novel solid state structure [Bi(8)(O(3)SMes)(20)(SO(4))(2)(H(2)O)(6)]·(C(7)H(8))(7)5·(C(7)H(8))(7), derived from the SM reaction under reflux conditions, is presented and the incorporation of the two inorganic sulfate anions in the centre of the wheel-like bismuth sulfonate cluster explained.

Recent advances in bioinorganic chemistry of bismuth

Bismuth has been used in medicine for over two centuries for the treatment of various diseases, in particular for gastrointestinal disorders, owing to its antimicrobial activity. Recent structural characterization of bismuth drugs provides an insight into assembly and pharmacokinetic pathway of the drugs. Mining potential protein targets inside the pathogen via metallomic/metalloproteomic approach and further characterization on the interactions of bismuth drugs with these targets laid foundation in understanding the mechanism of action of bismuth drugs. Such studies would be beneficial in rational design of new potential drugs.